uniQure (NASDAQ:QURE) Announces Earnings Results

uniQure (NASDAQ:QURE - Get Free Report) announced its quarterly earnings results on Friday. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.07) by $0.25, Zacks reports. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The firm had revenue of $1.57 million for the quarter, compared to the consensus estimate of $5.93 million.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $12.78 on Friday. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The firm has a fifty day moving average price of $12.22 and a 200-day moving average price of $12.09. The stock has a market cap of $700.04 million, a PE ratio of -2.58 and a beta of 0.10.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $291,628.89. Following the completion of the sale, the chief executive officer now directly owns 651,454 shares of the company's stock, valued at $6,703,461.66. This trade represents a 4.17 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Christian Klemt sold 2,916 shares of the business's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $33,009.12. Following the completion of the transaction, the chief financial officer now directly owns 155,168 shares in the company, valued at $1,756,501.76. This trade represents a 1.84 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 90,830 shares of company stock valued at $961,401. Company insiders own 4.74% of the company's stock.

Analysts Set New Price Targets

QURE has been the topic of several research reports. Wells Fargo & Company dropped their target price on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a report on Friday, February 28th. Chardan Capital reaffirmed a "buy" rating and issued a $38.00 price objective on shares of uniQure in a report on Tuesday, May 6th. HC Wainwright reissued a "buy" rating and issued a $70.00 target price on shares of uniQure in a report on Monday, April 21st. Royal Bank of Canada restated an "outperform" rating and set a $24.00 price target on shares of uniQure in a research note on Tuesday, January 21st. Finally, StockNews.com upgraded shares of uniQure to a "sell" rating in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $38.80.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.